Literature DB >> 22415467

Disease activity in systemic lupus erythematosus patients with end-stage renal disease: systematic review of the literature.

Patrícia Mattos1, Mittermayer B Santiago.   

Abstract

It is not unusual that patients with systemic lupus erythematosus (SLE) progress to terminal renal failure and subsequently require renal replacement therapy. Previous studies have shown that clinical and/or serological remission in patients with SLE is common in those who develop end-stage renal disease (ESRD). On the other hand, the persistence of lupus activity among patients undergoing long-term dialysis is not rare, either. The aim of this study is to define, by means of a systematic review, the course of SLE activity in patients who developed ESRD. Data were obtained through searches for articles in the MEDLINE (1966 to 2011), SCielo, and LILACS databases, using the following keywords: "chronic renal failure", "systemic lupus erythematosus", "end-stage renal disease", "lupus activity", "disease activity", "lupus flare", "hemodialysis", and "renal replacement therapy" and their corresponding translations in Portuguese. Twenty-four articles were found which evaluated the degree of lupus activity in patients with ESRD. Fifteen of these studies spoke of a substantial reduction of clinical and/or serological activity after the development of ESRD, while nine articles found that the amount of clinical and/or serological activity was similar to that of the phase prior to terminal renal failure, or it occurred in at least 50% of the patients studied. Although the majority of studies showed that lupus flares tend to decrease in frequency in patients who develop ESRD, in this scenario, one should be prepared to correctly diagnose a recurrence of the disease, as well as to perform appropriate therapy.

Entities:  

Mesh:

Year:  2012        PMID: 22415467     DOI: 10.1007/s10067-012-1957-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  35 in total

1.  Late-stage lupus nephropathy.

Authors:  J F Fries; R Powers; R L Kempson
Journal:  J Rheumatol       Date:  1974-06       Impact factor: 4.666

2.  Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity.

Authors:  J S Cheigh; H Kim; K H Stenzel; L Tapia; J F Sullivan; W Stubenbord; R R Riggio; A L Rubin
Journal:  Am J Kidney Dis       Date:  1990-09       Impact factor: 8.860

3.  The effect of maintenance dialysis on lymphocyte function. I. Haemodialysis.

Authors:  S R Holdsworth; M G Fitzgerald; C S Hosking; R C Atkins
Journal:  Clin Exp Immunol       Date:  1978-07       Impact factor: 4.330

4.  Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on SLE.

Authors:  H C Nossent; T J Swaak; J H Berden
Journal:  Am J Med       Date:  1990-08       Impact factor: 4.965

5.  Analysis of lupus activity in end-stage renal disease treated by hemodialysis.

Authors:  K Okano; W Yumura; K Nitta; K Uchida; T Ohnuki; A Kawashima; H Nihei
Journal:  Intern Med       Date:  2001-07       Impact factor: 1.271

6.  Poor prognosis of end-stage renal disease in systemic lupus erythematosus: a cohort of Chinese patients.

Authors:  Po-Tsang Lee; Hua-Chang Fang; Chien-Liang Chen; Yee-Hsuan Chiou; Kang-Ju Chou; Hsiao-Min Chung
Journal:  Lupus       Date:  2003       Impact factor: 2.911

7.  The evolution of lupus activity among patients with end-stage renal disease secondary to lupus nephritis.

Authors:  Young Suck Goo; Hyeong Cheon Park; Hoon Young Choi; Beom Seok Kim; Yong Beom Park; Soo-Kon Lee; Shin Wook Kang; Soon Il Kim; Yu Seun Kim; Ki Il Park; Ho Yung Lee; Dae Suk Han; Kyu Hun Choi
Journal:  Yonsei Med J       Date:  2004-04-30       Impact factor: 2.759

8.  The clinical course of end-stage renal disease in systemic lupus erythematosus.

Authors:  M P Jarrett; S Santhanam; F Del Greco
Journal:  Arch Intern Med       Date:  1983-07

9.  Morbidity of systemic lupus erythematosus: role of race and socioeconomic status.

Authors:  M Petri; S Perez-Gutthann; J C Longenecker; M Hochberg
Journal:  Am J Med       Date:  1991-10       Impact factor: 4.965

Review 10.  Systemic lupus erythematosus. Recognizing its various presentations.

Authors:  J M Von Feldt
Journal:  Postgrad Med       Date:  1995-04       Impact factor: 3.840

View more
  6 in total

Review 1.  Improving outcomes in patients with lupus and end-stage renal disease.

Authors:  Antonio Inda-Filho; Joel Neugarten; Chaim Putterman; Anna Broder
Journal:  Semin Dial       Date:  2013-09-04       Impact factor: 3.455

2.  Real-world electronic health record identifies antimalarial underprescribing in patients with lupus nephritis.

Authors:  W W Xiong; J B Boone; L Wheless; C P Chung; L J Crofford; A Barnado
Journal:  Lupus       Date:  2019-06-12       Impact factor: 2.911

3.  Disease Activity and Adverse Events in Patients with ANCA-Associated Vasculitides Undergoing Long-Term Dialysis.

Authors:  Maëlis Kauffmann; Mickaël Bobot; Thomas Robert; Stéphane Burtey; Grégoire Couvrat-Desvergnes; Frédéric Lavainne; Xavier Puéchal; Benjamin Terrier; Thomas Quéméneur; Stanislas Faguer; Alexandre Karras; Philippe Brunet; Cécile Couchoud; Noémie Jourde-Chiche
Journal:  Clin J Am Soc Nephrol       Date:  2021-11       Impact factor: 8.237

4.  Is schizophrenia associated with an increased risk of chronic kidney disease? A nationwide matched-cohort study.

Authors:  Nian-Sheng Tzeng; Yung-Ho Hsu; Shinn-Ying Ho; Yu-Ching Kuo; Hua-Chin Lee; Yun-Ju Yin; Hong-An Chen; Wen-Liang Chen; William Cheng-Chung Chu; Hui-Ling Huang
Journal:  BMJ Open       Date:  2015-01-27       Impact factor: 2.692

Review 5.  Management of End-stage Renal Disease Associated with Systemic Rheumatic Diseases.

Authors:  Suguru Honda; Yasuhiro Katsumata; Kazunori Karasawa; Hisashi Yamanaka; Masayoshi Harigai
Journal:  JMA J       Date:  2019-09-10

6.  Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.

Authors:  Maria Salgado Guerrero; Alejandra Londono Jimenez; Chrisanna Dobrowolski; Wenzhu B Mowrey; Beatrice Goilav; Shudan Wang; Anna Broder
Journal:  BMC Nephrol       Date:  2020-10-28       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.